Tenaya Therapeutics (TNYA) Capital Expenditures (2020 - 2026)

Tenaya Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$461000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 11425.0% year-over-year to -$461000.0 in Q1 2026; TTM through Mar 2026 was -$1.0 million, a 54.12% decrease from a year earlier, with the FY2025 full-year figure at -$571000.0, up 12.96% from the prior year.
• Capital Expenditures fell to -$461000.0 in Q1 2026 per TNYA's latest filing, from $2000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $19.7 million in Q3 2022 and bottomed at -$19.0 million in Q4 2022.
• The 5-year median for Capital Expenditures is $7000.0 (2024), against an average of -$16000.0.
• Across the five-year window, Capital Expenditures soared 2616.0% in 2023 and tumbled 11425.0% in 2026, its largest moves.
• Year by year, Capital Expenditures stood at -$19.0 million in 2022, then surged by 98.72% to -$244000.0 in 2023, then plunged by 505.33% to -$1.5 million in 2024, then soared by 100.14% to $2000.0 in 2025, then slumped by 23150.0% to -$461000.0 in 2026.
• Per Business Quant, the three latest TNYA Capital Expenditures figures stand at -$461000.0 (Q1 2026), $2000.0 (Q4 2025), and -$1.1 million (Q3 2025).